Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Highest Revenue

Below are the top drugs-generic stocks on the NASDAQ in terms of revenue. The trailing-twelve-month revenue at Mylan

is $6.39 billion. Mylan's ROA for the same period is 5.89%. The trailing-twelve-month revenue at Salix Pharmaceuticals Ltd

is $605.72 million. Salix Pharmaceuticals had $665.87 million in total cash for the latest quarter. The trailing-twelve-month revenue at Hi Tech Pharmacal Co

is $230.00 million. Hi Tech Pharmacal's ROE for the same period is 23.17%. The trailing-twelve-month revenue at Akorn

is $163.19 million. Akorn's operating margin for the same period is 26.68%.